Return to Publications
September 2016
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Helping Children with Blood Disorders 'Navigate' Their Care

Thanks to a two-year, $70,000 commitment from Embrace Kids Foundation, the Comprehensive Sickle Cell Center housed at Rutgers Cancer Institute of New Jersey is expanding to include a Pediatric Sickle Cell and Hemoglobinopathies Nurse Navigator position. The nurse navigator will help enhance patient services, remove barriers to care, and improve care coordination for families including educating families about their disease and treatment process and identifying clinical trials for which the patient may be eligible.

Justin Drake, PhD

A New Roadmap to Explore Treatment Targets for Advanced Prostate Cancer

Research from investigators at Rutgers Cancer Institute of New Jersey; University of California, Los Angeles; University of California, Santa Cruz and other institutions shows a computational approach examining abnormal "signaling" in prostate cancer tissues that is responsible for their spread and resistance to treatment and can help identify patient subsets for targeted therapies. Rutgers Cancer Institute researcher Justin Drake, PhD, assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, contributed to the work.

Eileen White, PhD and Jessie Guo, PhD

Cutting Off the Cancer Fuel Supply

Research from Rutgers Cancer Institute of New Jersey and Princeton University has identified a new approach to cancer therapy in cutting off a cancer cell's 'fuel supply' by targeting a cellular survival mechanism known as autophagy. Rutgers Cancer Institute Deputy Director Eileen P. White, PhD, distinguished professor of molecular biology and biochemistry in the School of Arts and Sciences at Rutgers University, and Rutgers Cancer Institute researcher 'Jessie' Yanxiang Guo, PhD, assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, are the co-corresponding authors of the work published in the August 10 edition of Genes & Development.

research leaders

Rutgers Cancer Institute Enhances Leadership of Research Programs

Expanding the leadership of its five core research programs, Rutgers Cancer Institute of New Jersey has announced new roles for research members serving as co-program leaders, spanning across three divisions: basic science, clinical science, and population science. New co-program leaders have been named to the Cancer Metabolism and Growth Program, the Genome Instability and Cancer Genetics Program, and the Cancer Prevention and Control Program.